With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.88511-37-9,1-(Isoxazol-3-yl)ethanone,as a common compound, the synthetic route is as follows.
88511-37-9, General procedure: To a solution of ketone A in THF cooled to -78 C, LiHMDS (e.g., 0.9 equiv, 1.0 M in toluene) was added dropwise via syringe. The reaction was allowed to warm to 0 C, then charged with diethyl oxalate (1.2 equiv). At this time, the reaction was warmed to room temperature and stirred at that temperature until judged complete (e.g., using either TLC or LC/MS analysis). Once the reaction was complete (reaction time was typically 45 minutes), the product dione enolate B was used “as-is” in Step 2, i.e., the cyclization step, without any further purification.
As the paragraph descriping shows that 88511-37-9 is playing an increasingly important role.
Reference£º
Patent; IRONWOOD PHARMACEUTICALS, INC.; BARDEN, Timothy Claude; SHEPPECK, James Edward; RENNIE, Glen Robert; RENHOWE, Paul Allan; PERL, Nicholas; NAKAI, Takashi; MERMERIAN, Ara; LEE, Thomas Wai-Ho; JUNG, Joon; JIA, James; IYER, Karthik; IYENGAR, Rajesh R.; IM, G-Yoon Jamie; (293 pag.)WO2016/44447; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem